Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907606 Target Snapshot

Mitogen-activated protein kinase; ERK1/ERK2 · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
554Compounds
341Assays
0Approved Drugs
204.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Mitogen-activated protein kinase; ERK1/ERK2 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P27361. Start with cancer, then reuse UniProt P27361 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P27361 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
cancer

Mitogen-activated protein kinase; ERK1/ERK2 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include KO-947, TEMUTERKIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase; ERK1/ERK2 as ChEMBL target CHEMBL1907606, mapped to UniProt P27361. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase; ERK1/ERK2
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1907606
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P27361
Mitogen-activated protein kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase; ERK1/ERK2 is the right protein anchor across sources, using UniProt P27361 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMitogen-activated protein kinase; ERK1/ERK2
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP27361
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase 3
UniProt AccessionP27361
Component TypeProtein
Sequence Length379 aa

Mitogen-activated protein kinase 3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase; ERK1/ERK2, mapped to UniProt P27361. ChEMBL maps the protein component as Mitogen-activated protein kinase 3. Sequence length is 379 aa.

Mapped IDP27361
Review nameMitogen-activated protein kinase; ERK1/ERK2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Mitogen-activated protein kinase; ERK1/ERK2 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block.

Clinical signal Phase II
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugKO-947
Linked drugTEMUTERKIB
Clinical signal Phase II
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTEMUTERKIB
Clinical signal Phase II
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTEMUTERKIB
Clinical signal Phase I
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugTEMUTERKIB
Mechanism-linked
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugTEMUTERKIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries clinical signal support. Linked drugs include KO-947, TEMUTERKIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50202.0
EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL318804 11.0 IC50 0.01 Preclinical
CHEMBL5439556 9.12 IC50 0.76 Preclinical
CHEMBL4482864 8.77 IC50 1.7 Preclinical
CHEMBL5396786 8.7 IC50 2.0 Preclinical
CHEMBL4212211 8.64 IC50 2.3 Preclinical
CHEMBL4858364 8.64 IC50 2.3 Preclinical
CHEMBL3590107 8.6 IC50 2.5 Preclinical
CHEMBL4440109 8.47 IC50 3.4 Preclinical
CHEMBL4452853 8.33 IC50 4.7 Preclinical
CHEMBL5430105 8.3 IC50 5.0 Preclinical
Distribution

pChEMBL Value Distribution

8
5.0
19
5.5
26
6.0
32
6.5
38
7.0
30
7.5
19
8.0
5
8.5
1
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

341
Total Assays
170
Tested Compounds
3
Assay Types
Binding — 335 assays, 170 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 293 161 7.0
protein format 36 8 5.3
assay format 5 1 8.0
tissue-based format 1 0 —
Functional — 4 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 2 8.7
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine